AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

genOway

CR
Bloomberg   ALGEN FP
Biomedical-Genetics  /  France  Web Site   |   Investors Relation
We have stopped researching genOway from 1 September 2019.